Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.
- 20 May 2017
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 4514